S&P 500   3,630.87 (+1.49%)
DOW   30,074.40 (+1.63%)
QQQ   292.98 (+0.89%)
AAPL   114.53 (+0.60%)
MSFT   212.70 (+1.23%)
FB   273.82 (+2.01%)
GOOGL   1,751.69 (+1.40%)
AMZN   3,111.28 (+0.42%)
TSLA   544.45 (+4.33%)
NVDA   517.04 (-1.63%)
BABA   276.93 (+2.52%)
CGC   26.60 (+7.61%)
GE   10.60 (+5.26%)
MU   63.40 (-1.22%)
AMD   84.66 (-0.76%)
T   29.35 (+2.55%)
NIO   53.24 (-3.86%)
F   9.41 (+6.21%)
ACB   8.85 (+23.26%)
NFLX   480.46 (+0.81%)
GILD   60.82 (+1.55%)
BA   220.85 (+4.41%)
DIS   150.82 (+3.32%)
S&P 500   3,630.87 (+1.49%)
DOW   30,074.40 (+1.63%)
QQQ   292.98 (+0.89%)
AAPL   114.53 (+0.60%)
MSFT   212.70 (+1.23%)
FB   273.82 (+2.01%)
GOOGL   1,751.69 (+1.40%)
AMZN   3,111.28 (+0.42%)
TSLA   544.45 (+4.33%)
NVDA   517.04 (-1.63%)
BABA   276.93 (+2.52%)
CGC   26.60 (+7.61%)
GE   10.60 (+5.26%)
MU   63.40 (-1.22%)
AMD   84.66 (-0.76%)
T   29.35 (+2.55%)
NIO   53.24 (-3.86%)
F   9.41 (+6.21%)
ACB   8.85 (+23.26%)
NFLX   480.46 (+0.81%)
GILD   60.82 (+1.55%)
BA   220.85 (+4.41%)
DIS   150.82 (+3.32%)
S&P 500   3,630.87 (+1.49%)
DOW   30,074.40 (+1.63%)
QQQ   292.98 (+0.89%)
AAPL   114.53 (+0.60%)
MSFT   212.70 (+1.23%)
FB   273.82 (+2.01%)
GOOGL   1,751.69 (+1.40%)
AMZN   3,111.28 (+0.42%)
TSLA   544.45 (+4.33%)
NVDA   517.04 (-1.63%)
BABA   276.93 (+2.52%)
CGC   26.60 (+7.61%)
GE   10.60 (+5.26%)
MU   63.40 (-1.22%)
AMD   84.66 (-0.76%)
T   29.35 (+2.55%)
NIO   53.24 (-3.86%)
F   9.41 (+6.21%)
ACB   8.85 (+23.26%)
NFLX   480.46 (+0.81%)
GILD   60.82 (+1.55%)
BA   220.85 (+4.41%)
DIS   150.82 (+3.32%)
S&P 500   3,630.87 (+1.49%)
DOW   30,074.40 (+1.63%)
QQQ   292.98 (+0.89%)
AAPL   114.53 (+0.60%)
MSFT   212.70 (+1.23%)
FB   273.82 (+2.01%)
GOOGL   1,751.69 (+1.40%)
AMZN   3,111.28 (+0.42%)
TSLA   544.45 (+4.33%)
NVDA   517.04 (-1.63%)
BABA   276.93 (+2.52%)
CGC   26.60 (+7.61%)
GE   10.60 (+5.26%)
MU   63.40 (-1.22%)
AMD   84.66 (-0.76%)
T   29.35 (+2.55%)
NIO   53.24 (-3.86%)
F   9.41 (+6.21%)
ACB   8.85 (+23.26%)
NFLX   480.46 (+0.81%)
GILD   60.82 (+1.55%)
BA   220.85 (+4.41%)
DIS   150.82 (+3.32%)
Log in
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$519.08
-4.53 (-0.87 %)
(As of 11/24/2020 12:16 PM ET)
Add
Compare
Today's Range
$518.83
Now: $519.08
$528.25
50-Day Range
$514.71
MA: $571.34
$607.98
52-Week Range
$328.13
Now: $519.08
$664.64
Volume19,332 shs
Average Volume1.12 million shs
Market Capitalization$55.39 billion
P/E Ratio20.10
Dividend YieldN/A
Beta0.51
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
Regeneron Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000
Employees8,142

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$21.56 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Market Cap$55.39 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$519.08
-4.53 (-0.87 %)
(As of 11/24/2020 12:16 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock price been impacted by COVID-19?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 12.1% and is now trading at $520.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals
.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported $8.36 earnings per share for the quarter, missing the consensus estimate of $9.52 by $1.16. The biopharmaceutical company had revenue of $2.29 billion for the quarter, compared to analysts' expectations of $2.09 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The company's quarterly revenue was up 31.6% compared to the same quarter last year. During the same period in the previous year, the company posted $6.67 EPS.
View Regeneron Pharmaceuticals' earnings history
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has approved a stock buyback plan on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

What price target have analysts set for REGN?

24 equities research analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $429.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $628.52 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 2,330,000 shares, an increase of 13.7% from the September 30th total of 2,050,000 shares. Based on an average trading volume of 857,000 shares, the short-interest ratio is currently 2.7 days. Approximately 2.3% of the shares of the company are sold short.
View Regeneron Pharmaceuticals' Short Interest
.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 67, Pay $4.77M)
  • Dr. George D. Yancopoulos, Co-Founder, Pres & Chief Scientific Officer & Director (Age 60, Pay $3.98M)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 56, Pay $1.56M)
  • Dr. Andrew J. Murphy, Exec. VP of Research (Age 62, Pay $1.29M)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 47, Pay $1.46M)
  • Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
  • Mr. Gerald Underwood, Sr. VP of Technical Operations
  • Justin Holko, VP of Investor Relations
  • Mr. Joseph J. LaRosa, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Ms. Beth F. Levine, Sr. VP, Associate Gen. Counsel & Chief Compliance Officer (Age 56)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.20%), State Street Corp (4.38%), Nuveen Asset Management LLC (1.53%), Sands Capital Management LLC (0.80%), California Public Employees Retirement System (0.78%) and UBS Asset Management Americas Inc. (0.56%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Natixis, Nuveen Asset Management LLC, Polar Capital LLP, Polar Capital LLP, Sustainable Growth Advisers LP, DNB Asset Management AS, LSV Asset Management, and Neuberger Berman Group LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, AQR Capital Management LLC, Candriam Luxembourg S.C.A., Swiss National Bank, UBS Asset Management Americas Inc., Voloridge Investment Management LLC, KBC Group NV, and Wells Fargo & Company MN.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $520.70.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $55.56 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,142 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.